Clinical Trial Update: A Human Volunteer Study Investigating Single Oral Doses of GSK598809 in Otherwise Healthy Smokers [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety, tolerability, and pharmacokinetics of single oral doses of GSK598809 in otherwise healthy smokers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Substance Dependence

Drugs mentioned

• GSK598809 (GSK598809)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Substance Dependence | Phase 1 | Status: COMPLETED